Drug search by name

Aprepitant Oral Suspension and Liver disease

Generic Name: aprepitant
Dosage Forms: n.a.
Other Brand Names: Cinvanti , Emend , Emend 3-Day, Emend 2-Day

Result of checking the interaction of drug Aprepitant Oral Suspension and disease Liver disease for safety when used together.

Check result:

Aprepitant Oral Suspension <> Liver disease

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Aprepitant is primarily metabolized by the liver. In studies of patients with mild to moderate hepatic impairment (Child-Pugh score 5 to 9), aprepitant was well tolerated and no clinically significant alterations in its pharmacokinetics were observed. Thus, no dosage adjustment of aprepitant is necessary in this patient population. However, there are no clinical or pharmacokinetic data in patients with severe hepatic impairment (Child-Pugh score > 9), and caution is advised if aprepitant is used in such patients.

References: